Zytiga

J&J’s Erleada first US drug for non-metastatic prostate cancer

momentum before Zytiga (abiraterone acetate) - its current blockbuster medicine for CRPC - faces generic competition in the US, which accounted for around half of the drug’s $2.5bn in sales in

PROSPER data reveal big Xtandi benefit in early-stage prostate cancer

At the moment Xtandi, in common with a rival therapy from Johnson &Johnson called Zytiga (abiraterone acetate), is only prescribed for men with advanced CRPC that has spread and no longer ... The market category will see some significant disruption later

EC expands Janssen’s prostate cancer drug reach

Zytiga plus predinson/prednisolone will now treat mHSPC patients. Janssen has chalked up a significant win in the European market following a ruling on its prostate cancer drug Zytiga (abiraterone acetate), ... However, the European Commission’s

CHMP recommends Teva's generic version of Astellas' Advagraf

Finally, both Roche and Janssen got the nod for wider licences for Pegasys (peginterferon) and Zytiga (abiraterone acetate), respectively. ... While Zytiga has been recommended to treat newly diagnosed high-risk metastatic hormone sensitive prostate

Pfizer hits accelerator on Xtandi trial in early prostate cancer

by almost two years as they fight for market share with Johnson &Johnson's rival Zytiga therapy. ... Analysts have suggested that with the new data Zytiga could see a resurgence, potentially pushing sales above the $3bn mark.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]